HOSPITAL PROFILE

HOSPITAL PROFILE

The Eastern Hepatobiliary Surgery Hospital(EHBH)，including the Eastern Institute for Hepatobiliary Surgery Research，is the 3rdaffiliated hospital of the Second Military Medical University of the Chinese People’s Liberation Army(CPLA).Through self-reliance，hard working，unyielding efforts and dashing spirit for more than 50 years under the leadership of Professor WU Mengchao，a world-famous expert in hepatobiliary surgery，one of the main pioneers and originators of hepatobiliary surgery in China，and a member of the Chinese Academy of Sciences，EHBH has grown from a three-person group in 1956 to the only hepatobiliary surgery specialist hospital with a built-in research institute in China that merges medical care services，training and scientific research into an integral framework.It has become a national key discipline，a state-level base for continuing medical education，a CPLA hepatobiliary surgery center，a CPLA institute for hepatobiliary surgery research，a key laboratory of the Ministry of Education and CPLA，and a CPLA “primary key discipline”，a leading key discipline in medical science in Shanghai.Approved as a“Class III Grade A”specialist hospital by the CPLA General Logistics Department.Now the hospital has 742 beds and is equipped with the latest instruments and equipment with a total value of RMB two hundred million yuan.EHBH has reached the international level and the leading domestic level in the early detection and early treatment of primary liver cancer，comprehensive treatment of middle-advanced stage liver cancer，postoperative anti-recurrence therapy of primary liver cancer，immunotherapeutic interventions against tumors，surgical treatment of complex hepatobiliary diseases，endoscopic treatment of hepatobiliary diseases，and liver transplantation.

Now the yearly outpatient capacity is about 160 000 persons/times，and the yearly number of hospitalized patients is more than 24 000 persons/times.By December 2011，Dr.WU Mengchao and his colleagues had successfully performed more than 70 000 operations and set up the largest case-bank and specimen-bank of liver cancer in the world.The success rate of liver tumor resection is as high as 99%;the postoperative 5-year overall survival rate is 53.2%;the postoperative 5-year survival rate for small liver cancer is over 80%;and the longest postoperative survival is over 44 years.The hospital tops the world in the number of liver cancer resections，the resection rate and the survival rate.

The hospital has an army of experienced technical personnel with tip-top young talents as the mainstay under the leadership of Academician WU Mengchao，including 71 persons with senior professional titles，a member of the Chinese Academy of Sciences and a member of the Chinese Academy of Engineering.In January 1996，the Chinese Central Military Commission granted WU Mengchao the honorary title“Model Medical Experts”.Other honorary titles and awards won by the staff members of the hospital and the institute include:Distinguished Professor of Cheung Kong Scholars Program(1 person);and so on.

Since 1978，the hospital has trained 20 post-doctoral graduates，143 PhD graduates and 254 master’s degree graduates.In addition，it also undertakes teaching tasks of training overseas students and graduating students majoring in clinical medicine.For many years，the hospital has trained more than one thousand trainees from all parts of the country，and has become a national teaching base for cultivating senior personnel in hepatobiliary surgery.The hospital has won various science and technology prizes and awards，including State Supreme Science and Technology Award(1 project);National Science and Technology Assembly Award(1 project);and so on.

The Eastern Institute for Hepatobiliary Surgery Research headed by Professor WU Mengchao is a CPLA scientific research，medical care service and training center.It is among the first batch of disciplines authorized to confer Master’s Degree in 1979 and Doctoral Degree in 1981 after China resumed the national postgraduate enrollment.In 1991，it was approved as the CPLA open laboratory and the postdoctoral mobile research station of clinical medicine.The institute comprises an institute for anti-tumor immunogene therapy，a biological signal transduction research center，a molecular oncology research room and a virus-based gene therapy laboratory.

Faced with the growing community health needs and the rapid advances in medical science，the hospital spares no effort to seize the opportunity by investing RMB 1.6 billion yuan to build a new hospital in Anting of Shanghai Jiading District.Equipped with 1 500 beds(1 000 beds for the stage-one project)，the new hospital will be a Class III Grade A tertiary general hospital with a complete lists of affiliated units and departments characteristic of distinctive specialty traits.

Co-funded by more than RMB 4 hundred million yuan from the State Development and Reform Commission and Shanghai Government，the State Liver Cancer Center will be settled in Anting，covering an area of 40 acres adjacent to the new hospital.It will serve as a public service platform for liver cancer science，and a national academic exchange and cooperation center.

醫(yī)院簡介

第二軍醫(yī)大學(xué)東方肝膽外科醫(yī)院是著名肝膽外科專家、我國肝膽外科主要奠基人和開拓者、中國科學(xué)院院士吳孟超教授創(chuàng)建并領(lǐng)導(dǎo)的院所合一、國內(nèi)唯一的肝膽外科專科醫(yī)院，現(xiàn)為國家重點(diǎn)學(xué)科，國家級(jí)繼續(xù)醫(yī)學(xué)教育基地，全軍肝膽外科?？浦行模姼文懲饪蒲芯克瑖医逃亢腿娭攸c(diǎn)實(shí)驗(yàn)室，軍隊(duì)“重中之重”建設(shè)學(xué)科，上海市醫(yī)學(xué)領(lǐng)先專業(yè)重點(diǎn)學(xué)科，上海市重中之重臨床醫(yī)學(xué)中心。開放床位712張，擁有各類先進(jìn)儀器設(shè)備價(jià)值1.58億元。

醫(yī)院長期堅(jiān)持醫(yī)、教、研結(jié)合，在原發(fā)性肝癌的早期診斷和治療，中晚期肝癌的綜合治療，原發(fā)性肝癌術(shù)后抗復(fù)發(fā)治療，腫瘤的免疫治療、介入治療，復(fù)雜膽道疾病的手術(shù)治療，肝膽疾病的內(nèi)窺鏡治療，以及肝移植等方面均居國內(nèi)外先進(jìn)水平。

醫(yī)院現(xiàn)年門診量19萬多人次，年收治住院病人2.6萬余人次。至2012年11月止，已成功實(shí)施手術(shù)7.5萬余例，積累了國際上最大數(shù)量的肝癌病例庫和標(biāo)本庫，肝癌切除手術(shù)成功率達(dá)到99%，術(shù)后5年總生存率達(dá)53.2%，小肝癌術(shù)后5年生存率達(dá)80%以上，術(shù)后生存時(shí)間最長的已達(dá)44年。肝癌切除例數(shù)、切除率、生存率等指標(biāo)均處于國際領(lǐng)先水平。

醫(yī)院擁有一支由吳孟超院士領(lǐng)銜，以拔尖中青年為骨干的優(yōu)秀科技干部隊(duì)伍，現(xiàn)有高級(jí)職稱95名，中國科學(xué)院院士1名，中國工程院院士1名，博士生導(dǎo)師26名，碩士生導(dǎo)師51名。共培養(yǎng)博士后22名，博士研究生151名，碩士研究生261名，為全國各地培養(yǎng)進(jìn)修生千余名。獲國家最高科學(xué)技術(shù)獎(jiǎng)1項(xiàng)，全國科技大會(huì)獎(jiǎng)1項(xiàng)，國家科技進(jìn)步一、二、三等獎(jiǎng)5項(xiàng)，國家自然科學(xué)二等獎(jiǎng)1項(xiàng)，獲省部級(jí)科技進(jìn)步和醫(yī)療成果獎(jiǎng)92項(xiàng)。“十一五”以來獲各類課題資助278項(xiàng)，資助經(jīng)費(fèi)近3.45億元。2012年獲國家首次設(shè)立的科技進(jìn)步創(chuàng)新團(tuán)隊(duì)獎(jiǎng)。

醫(yī)院創(chuàng)始人吳孟超院士1996年1月被中央軍委授予“模范醫(yī)學(xué)專家”榮譽(yù)稱號(hào)，2006年1月獲國家最高科學(xué)技術(shù)獎(jiǎng)，2012年被評(píng)為“感動(dòng)中國”人物。近年來，醫(yī)院先后被評(píng)為總后勤部“先進(jìn)黨委“、“先進(jìn)師旅團(tuán)級(jí)單位”、“貫徹科學(xué)發(fā)展先進(jìn)單位”和“全軍醫(yī)院管理先進(jìn)單位”。2008年醫(yī)院抗震救災(zāi)醫(yī)療隊(duì)榮立二等功。

東方肝膽外科研究所作為軍隊(duì)科研、醫(yī)學(xué)和教學(xué)的中心，1979年、1981年分別被批準(zhǔn)為國家恢復(fù)研究生制度后的第一批碩士、博士授權(quán)學(xué)科。下設(shè)腫瘤免疫與基因治療研究所、生物信號(hào)轉(zhuǎn)導(dǎo)研究中心、分子腫瘤研究室、病毒與基因治療實(shí)驗(yàn)室，在肝膽外科及肝癌的基礎(chǔ)和臨床研究方面始終起著引領(lǐng)作用。

安亭新院規(guī)劃床位1 500張，一期工程(1 000張)在2013年投入使用，總建筑面積22.28萬平方米。

國家肝癌科學(xué)中心項(xiàng)目建設(shè)全面推進(jìn)，中心將建設(shè)成為國家肝癌集成研究中心、國家肝癌研究優(yōu)勢資源產(chǎn)業(yè)平臺(tái)、高層次肝癌研究人才培養(yǎng)基地、國家肝癌科學(xué)的公共服務(wù)平臺(tái)和國家學(xué)術(shù)交流與合作中心。